Gregory W. Sawyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gregory W. Sawyer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Frederick J. Ehlert
University of California
7 shared publications- Frederick J. Ehlert
Department of Pharmacology, School of Medicine, University of California, Irvine, CA 92697-4625, USA
3 shared publications Crystal A. Shults
2 shared publicationsDavid C. Chiara
2 shared publications- Richard W. Olsen
University of California, Los Angeles, California, U.S.A.
2 shared publications Arunkumar Thangaraju
Oklahoma State University, Center for Health Sciences, College of Osteopathic Medicine, Department of Biochemistry and Microbiology, 1111 W. 17th Street, Tulsa, OK 74107-1898, USA
1 shared publication
Latest Publications
- 24 December 2013
- Published by Springer Nature
- p. 177-195
Using In Vitro Mutagenesis to Characterize Structure-Function Relationships in G Protein-Coupled Receptors
- 24 December 2013
- Published by Springer Nature
- p. 177-195
Using In Vitro Mutagenesis to Characterize Structure-Function Relationships in G Protein-Coupled Receptors
- 7 June 2011
- Published by Springer Nature
- p. 187-207
A Novel Method for Determining the Kinetics of G Protein-Coupled Receptor Plasma Membrane Expression
- 7 June 2011
- Published by Springer Nature
- p. 187-207
A Novel Method for Determining the Kinetics of G Protein-Coupled Receptor Plasma Membrane Expression
- 31 October 2010
- Published by Elsevier in European Journal of Pharmacology
- Vol. 650 (2-3) , 534-543
Comparison of the kinetics and extent of muscarinic M1–M5 receptor internalization, recycling and downregulation in Chinese hamster ovary cells
- 31 October 2010
- Published by Elsevier in European Journal of Pharmacology
- Vol. 650 (2-3) , 534-543
Comparison of the kinetics and extent of muscarinic M1–M5 receptor internalization, recycling and downregulation in Chinese hamster ovary cells
- 1 October 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (4) , 745-755
Mutagenesis of Nucleophilic Residues near the Orthosteric Binding Pocket of M1 and M2 Muscarinic receptors: Effect on the Binding of Nitrogen Mustard Analogs of Acetylcholine and McN-A-343
Investigating how a test drug alters the reaction of a site-directed electrophile with a receptor is a powerful method for determining whether the drug acts competitively or allosterically, provided that the binding site of the electrophile is known. In this study, therefore, we mutated nucleophilic residues near and within the orthosteric pockets of M1 and M2 muscarinic receptors to identify where acetylcholine mustard and 4-[(2-bromoethyl)methyl-amino]-2-butynyl-N-(3-chlorophenyl)carbamate (BR384) bind covalently. BR384 is the nitrogen mustard analog of [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride (McN-A-343). Mutation of the highly conserved aspartic acid in M1 (Asp105) and M2 (Asp103) receptors to asparagine largely prevented receptor alkylation by acetylcholine mustard, although modest alkylation still occurred at M2 D103N at high concentrations of the mustard. Receptor alkylation by BR384 was also greatly inhibited in the M1 D105N mutant, but some alkylation still occurred at high concentrations of the compound. In contrast, BR384 rapidly alkylated the M2 D103N mutant. Its affinity was reduced to one tenth, however. The alkylation of M2 D103N by BR384 was competitively inhibited by N-methylscopolamine and allosterically inhibited by gallamine. Mutation of a variety of other nucleophilic residues, some in combination with D103N, had little effect on M2 receptor alkylation by BR384. Our results suggest that BR384 alkylates at least one residue other than the conserved aspartic acid at the ligand-binding site of M1 and M2 receptors. This additional residue seems to be located within or near the orthosteric-binding pocket and is not part of the allosteric site for gallamine.
- 1 October 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (4) , 745-755
Mutagenesis of Nucleophilic Residues near the Orthosteric Binding Pocket of M1 and M2 Muscarinic receptors: Effect on the Binding of Nitrogen Mustard Analogs of Acetylcholine and McN-A-343
Investigating how a test drug alters the reaction of a site-directed electrophile with a receptor is a powerful method for determining whether the drug acts competitively or allosterically, provided that the binding site of the electrophile is known. In this study, therefore, we mutated nucleophilic residues near and within the orthosteric pockets of M1 and M2 muscarinic receptors to identify where acetylcholine mustard and 4-[(2-bromoethyl)methyl-amino]-2-butynyl-N-(3-chlorophenyl)carbamate (BR384) bind covalently. BR384 is the nitrogen mustard analog of [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride (McN-A-343). Mutation of the highly conserved aspartic acid in M1 (Asp105) and M2 (Asp103) receptors to asparagine largely prevented receptor alkylation by acetylcholine mustard, although modest alkylation still occurred at M2 D103N at high concentrations of the mustard. Receptor alkylation by BR384 was also greatly inhibited in the M1 D105N mutant, but some alkylation still occurred at high concentrations of the compound. In contrast, BR384 rapidly alkylated the M2 D103N mutant. Its affinity was reduced to one tenth, however. The alkylation of M2 D103N by BR384 was competitively inhibited by N-methylscopolamine and allosterically inhibited by gallamine. Mutation of a variety of other nucleophilic residues, some in combination with D103N, had little effect on M2 receptor alkylation by BR384. Our results suggest that BR384 alkylates at least one residue other than the conserved aspartic acid at the ligand-binding site of M1 and M2 receptors. This additional residue seems to be located within or near the orthosteric-binding pocket and is not part of the allosteric site for gallamine.
- 1 January 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 332 (1) , 76-86
A Conserved Motif in the Membrane Proximal C-Terminal Tail of Human Muscarinic M1 Acetylcholine Receptors Affects Plasma Membrane Expression
We investigated the functional role of a conserved motif, F(x)6LL, in the membrane proximal C-tail of the human muscarinic M1 (hM1) receptor. By use of site-directed mutagenesis, several different point mutations were introduced into the C-tail sequence 423FRDTFRLLL431. Wild-type and mutant hM1 receptors were transiently expressed in Chinese hamster ovary cells, and the amount of plasma membrane-expressed receptor was determined by use of intact, whole-cell [3H]N-methylscopolamine binding assays. The plasma membrane expression of hM1 receptors possessing either L430A or L431A or both point mutations was significantly reduced compared with the wild type. The hM1 receptor possessing a L430A/L431A double-point mutation was retained in the endoplasmic reticulum (ER), and atropine treatment caused the redistribution of the mutant receptor from the ER to the plasma membrane. Atropine treatment also caused an increase in the maximal response and potency of carbachol-stimulated phosphoinositide hydrolysis elicited by the L430A/L431A mutant. The effect of atropine on the L430A/L431A receptor mutant suggests that L430 and L431 play a role in folding hM1 receptors, which is necessary for exit from the ER. Using site-directed mutagenesis, we also identified amino acid residues at the base of transmembrane-spanning domain 1 (TM1), V46 and L47, that, when mutated, reduce the plasma membrane expression of hM1 receptors in an atropine-reversible manner. Overall, these mutagenesis data show that amino acid residues in the membrane-proximal C-tail and base of TM1 are necessary for hM1 receptors to achieve a transport-competent state.
- 1 January 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 332 (1) , 76-86
A Conserved Motif in the Membrane Proximal C-Terminal Tail of Human Muscarinic M1 Acetylcholine Receptors Affects Plasma Membrane Expression
We investigated the functional role of a conserved motif, F(x)6LL, in the membrane proximal C-tail of the human muscarinic M1 (hM1) receptor. By use of site-directed mutagenesis, several different point mutations were introduced into the C-tail sequence 423FRDTFRLLL431. Wild-type and mutant hM1 receptors were transiently expressed in Chinese hamster ovary cells, and the amount of plasma membrane-expressed receptor was determined by use of intact, whole-cell [3H]N-methylscopolamine binding assays. The plasma membrane expression of hM1 receptors possessing either L430A or L431A or both point mutations was significantly reduced compared with the wild type. The hM1 receptor possessing a L430A/L431A double-point mutation was retained in the endoplasmic reticulum (ER), and atropine treatment caused the redistribution of the mutant receptor from the ER to the plasma membrane. Atropine treatment also caused an increase in the maximal response and potency of carbachol-stimulated phosphoinositide hydrolysis elicited by the L430A/L431A mutant. The effect of atropine on the L430A/L431A receptor mutant suggests that L430 and L431 play a role in folding hM1 receptors, which is necessary for exit from the ER. Using site-directed mutagenesis, we also identified amino acid residues at the base of transmembrane-spanning domain 1 (TM1), V46 and L47, that, when mutated, reduce the plasma membrane expression of hM1 receptors in an atropine-reversible manner. Overall, these mutagenesis data show that amino acid residues in the membrane-proximal C-tail and base of TM1 are necessary for hM1 receptors to achieve a transport-competent state.
- Open Access
- 1 January 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (1) , 196-205
Cysteine Pairs in the Third Intracellular Loop of the Muscarinic M1 Acetylcholine Receptor Play a Role in Agonist-Induced Internalization
We determined the functional role of a small domain in the third intracellular loop of the human muscarinic M1 (hM1) receptor. Using site-directed mutagenesis, several mutant hM1 receptors were made possessing either a deletion or point mutations within the third intracellular loop domain 252PETPPGRCCRCC263. Wild-type and mutant hM1 receptors were transiently expressed in Chinese hamster ovary cells, and the effects of each mutation on radioligand binding, agonist-mediated phosphoinositide hydrolysis, and agonist-induced internalization were determined. The mutant receptors exhibited a modest reduction in affinity for [3H]N-methylscopolamine (pKD = ∼9.0) and a moderately increased binding capacity relative to the wild-type receptor. This moderate increase in binding capacity was associated with small increases in the maximal response and potency of carbachol for eliciting phosphoinositide hydrolysis through the mutant receptors (pEC50 = ∼5.5) relative to wild-type (pEC50 = 5.35 ± 0.05). In contrast, carbachol-induced internalization of mutant hM1 receptors possessing either C259A/C260A or C262A/C263A or both double point mutations was significantly reduced compared to the wild-type hM1 receptor. Of the hM1 receptor mutants tested, those possessing a C262D/C263D double point mutation had the least carbachol-induced internalization. The desensitization and down-regulation of receptors possessing either Cys/Ala or Cys/Asp double point mutations were similar to those observed for the wild-type hM1 receptor. Collectively, these observations suggest that Cys pairs Cys259/Cys260 and Cys262/Cys263 play an important role in the agonist-induced internalization of hM1 receptors.
- 1 January 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (1) , 196-205
Open AccessCysteine Pairs in the Third Intracellular Loop of the Muscarinic M1 Acetylcholine Receptor Play a Role in Agonist-Induced Internalization
We determined the functional role of a small domain in the third intracellular loop of the human muscarinic M1 (hM1) receptor. Using site-directed mutagenesis, several mutant hM1 receptors were made possessing either a deletion or point mutations within the third intracellular loop domain 252PETPPGRCCRCC263. Wild-type and mutant hM1 receptors were transiently expressed in Chinese hamster ovary cells, and the effects of each mutation on radioligand binding, agonist-mediated phosphoinositide hydrolysis, and agonist-induced internalization were determined. The mutant receptors exhibited a modest reduction in affinity for [3H]N-methylscopolamine (pKD = ∼9.0) and a moderately increased binding capacity relative to the wild-type receptor. This moderate increase in binding capacity was associated with small increases in the maximal response and potency of carbachol for eliciting phosphoinositide hydrolysis through the mutant receptors (pEC50 = ∼5.5) relative to wild-type (pEC50 = 5.35 ± 0.05). In contrast, carbachol-induced internalization of mutant hM1 receptors possessing either C259A/C260A or C262A/C263A or both double point mutations was significantly reduced compared to the wild-type hM1 receptor. Of the hM1 receptor mutants tested, those possessing a C262D/C263D double point mutation had the least carbachol-induced internalization. The desensitization and down-regulation of receptors possessing either Cys/Ala or Cys/Asp double point mutations were similar to those observed for the wild-type hM1 receptor. Collectively, these observations suggest that Cys pairs Cys259/Cys260 and Cys262/Cys263 play an important role in the agonist-induced internalization of hM1 receptors.
- Open Access
- 8 November 2006
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 26 (45) , 11599-11605
Identification of a GABAAReceptor Anesthetic Binding Site at Subunit Interfaces by Photolabeling with an Etomidate Analog
General anesthetics, including etomidate, act by binding to and enhancing the function of GABA type A receptors (GABAARs), which mediate inhibitory neurotransmission in the brain. Here, we used a radiolabeled, photoreactive etomidate analog ([3H]azietomidate), which retains anesthetic potencyin vivoand enhances GABAAR functionin vitro, to identify directly, for the first time, amino acids that contribute to a GABAAR anesthetic binding site. For GABAARs purified by affinity chromatography from detergent extracts of bovine cortex, [3H]azietomidate photoincorporation was increased by GABA and inhibited by etomidate in a concentration-dependent manner (IC50= 30 μm). Protein microsequencing of fragments isolated from proteolytic digests established photolabeling of two residues: one within the αM1 transmembrane helix at α1Met-236 (and/or the homologous methionines in α2,3,5), not previously implicated in etomidate function, and one within the βM3 transmembrane helix at β3Met-286 (and/or the homologous methionines in β1,2), an etomidate sensitivity determinant. The pharmacological specificity of labeling indicates that these methionines contribute to a single binding pocket for etomidate located in the transmembrane domain at the interface between β and α subunits, in what is predicted by structural models based on homology with the nicotinic acetylcholine receptor to be a water-filled pocket ∼50 Å below the GABA binding site. The localization of the etomidate binding site to an intersubunit, not an intrasubunit, binding pocket is a novel conclusion that suggests more generally that the localization of drug binding sites to subunit interfaces may be a feature not only for GABA and benzodiazepines but also for etomidate and other intravenous and volatile anesthetics.
- 8 November 2006
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 26 (45) , 11599-11605
Open AccessIdentification of a GABAAReceptor Anesthetic Binding Site at Subunit Interfaces by Photolabeling with an Etomidate Analog
General anesthetics, including etomidate, act by binding to and enhancing the function of GABA type A receptors (GABAARs), which mediate inhibitory neurotransmission in the brain. Here, we used a radiolabeled, photoreactive etomidate analog ([3H]azietomidate), which retains anesthetic potencyin vivoand enhances GABAAR functionin vitro, to identify directly, for the first time, amino acids that contribute to a GABAAR anesthetic binding site. For GABAARs purified by affinity chromatography from detergent extracts of bovine cortex, [3H]azietomidate photoincorporation was increased by GABA and inhibited by etomidate in a concentration-dependent manner (IC50= 30 μm). Protein microsequencing of fragments isolated from proteolytic digests established photolabeling of two residues: one within the αM1 transmembrane helix at α1Met-236 (and/or the homologous methionines in α2,3,5), not previously implicated in etomidate function, and one within the βM3 transmembrane helix at β3Met-286 (and/or the homologous methionines in β1,2), an etomidate sensitivity determinant. The pharmacological specificity of labeling indicates that these methionines contribute to a single binding pocket for etomidate located in the transmembrane domain at the interface between β and α subunits, in what is predicted by structural models based on homology with the nicotinic acetylcholine receptor to be a water-filled pocket ∼50 Å below the GABA binding site. The localization of the etomidate binding site to an intersubunit, not an intrasubunit, binding pocket is a novel conclusion that suggests more generally that the localization of drug binding sites to subunit interfaces may be a feature not only for GABA and benzodiazepines but also for etomidate and other intravenous and volatile anesthetics.
- 1 May 2006
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 53 (3) , 219-233
Determination of the rate of muscarinic M1 receptor plasma membrane delivery using a regulated secretion/aggregation system
- 1 May 2006
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 53 (3) , 219-233
Determination of the rate of muscarinic M1 receptor plasma membrane delivery using a regulated secretion/aggregation system
- Open Access
- 1 December 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (51) , 50036-50045
Identification of the Bovine γ-Aminobutyric Acid Type A Receptor α Subunit Residues Photolabeled by the Imidazobenzodiazepine [3H]Ro15-4513
- 1 December 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (51) , 50036-50045
Open AccessIdentification of the Bovine γ-Aminobutyric Acid Type A Receptor α Subunit Residues Photolabeled by the Imidazobenzodiazepine [3H]Ro15-4513
- Open Access
- 1 April 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (7) , 1458-1464
Functional role of muscarinic M2 receptors in α,β -methylene ATP induced, neurogenic contractions in guinea-pig ileum
- 1 April 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (7) , 1458-1464
Open AccessFunctional role of muscarinic M2 receptors in α,β -methylene ATP induced, neurogenic contractions in guinea-pig ileum